Kolexia
Xerri Luc Anatomie et cytologie
Xerri Luc
Anatomie et cytologie
Centre Paoli-Calmettes
Marseille, France
147 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome folliculaire Lymphome B Maladie de Hodgkin Lymphome à grandes cellules anaplasiques Lymphome malin non hodgkinien Lymphome T Tumeurs du sein Lymphome B diffus à grandes cellules

Collaborateurs

Voir plus
Salles Gilles
Salles Gilles
Hôpital Lyon Sud, Pierre-Bénite, France
Haioun Corinne
Haioun Corinne
Hôpital Henri Mondor, Créteil, France
Tilly Herve
Tilly Herve
Centre Henri-Becquerel, Rouen, France
Bouabdallah Reda
Bouabdallah Reda
Cabinet libéral, Aix-en-Provence, France

Industries

Voir plus
Eusa Pharma
21 collaboration(s)
Dernière en 2023
Janssen
2 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
1 collaboration(s)
Dernière en 2023
Bouchara-Recordati
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
The Journal of pathology   05 janvier 2024
Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy
65th ASH Annual Meeting Abstracts   02 novembre 2023
Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748.
Leukemia   28 août 2023
RELEVANCE: A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Essai Clinique (Celgene)   10 août 2023
The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, Nice, France).
Journal of personalized medicine   29 juin 2023
Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups)
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Identification of an activated/memory B-cell signature of poor outcome and sensitivity to lenalidomide in follicular lymphoma patients
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.
British journal of haematology   22 mai 2023